MX2017000836A - Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. - Google Patents

Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.

Info

Publication number
MX2017000836A
MX2017000836A MX2017000836A MX2017000836A MX2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A MX 2017000836 A MX2017000836 A MX 2017000836A
Authority
MX
Mexico
Prior art keywords
listeria
tumor
immunogenic compositions
tumor responses
eliciting anti
Prior art date
Application number
MX2017000836A
Other languages
English (en)
Inventor
Wallecha Anu
Petit Robert
Chen Zhisong
A Berzofsky Jay
KHLEIF Samir
Original Assignee
Advaxis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Advaxis Inc filed Critical Advaxis Inc
Publication of MX2017000836A publication Critical patent/MX2017000836A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6068—Other bacterial proteins, e.g. OMP
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención se refiere a composiciones que comprenden un inhibidor de un punto de regulación inmunológico o un estimulador de células T o una combinación de estos y una cepa de Listeria recombinante atenuada viva que comprende un polipéptido de fusión que comprende una proteína Listeriolisina O truncada, una proteína ActA truncada, o una secuencia de aminoácidos PEST fusionada a un antígeno asociado al tumor. La invención se refiere, además, a métodos para tratar, proteger contra, e inducir una respuesta inmunitaria contra un tumor o un cáncer, que comprende la etapa de administrar esta.
MX2017000836A 2014-07-18 2015-07-17 Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales. MX2017000836A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462026221P 2014-07-18 2014-07-18
PCT/US2015/040922 WO2016011362A1 (en) 2014-07-18 2015-07-17 Listeria-based immunogenic compositions for eliciting anti-tumor responses

Publications (1)

Publication Number Publication Date
MX2017000836A true MX2017000836A (es) 2017-11-17

Family

ID=55079089

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2017000836A MX2017000836A (es) 2014-07-18 2015-07-17 Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.

Country Status (12)

Country Link
US (1) US20180064765A1 (es)
EP (1) EP3169355A4 (es)
JP (1) JP2017522322A (es)
KR (1) KR20170063505A (es)
CN (1) CN106794235A (es)
AU (1) AU2015289449A1 (es)
CA (1) CA2955432A1 (es)
IL (1) IL249671A0 (es)
MA (1) MA40061A (es)
MX (1) MX2017000836A (es)
SG (1) SG11201700090RA (es)
WO (1) WO2016011362A1 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9012141B2 (en) 2000-03-27 2015-04-21 Advaxis, Inc. Compositions and methods comprising KLK3 of FOLH1 antigen
CA2829960A1 (en) 2011-03-11 2012-09-20 John Rothman Listeria-based adjuvants
WO2013138337A1 (en) 2012-03-12 2013-09-19 Advaxis Suppressor cell function inhibition following listeria vaccine treatment
CN106456726A (zh) 2014-02-18 2017-02-22 阿德瓦希斯公司 生物标志物导向的多靶点免疫治疗
SG10202011841WA (en) 2014-04-24 2021-01-28 Advaxis Inc Recombinant listeria vaccine strains and methods of producing the same
MA41644A (fr) 2015-03-03 2018-01-09 Advaxis Inc Compositions à base de listeria comprenant un système d'expression de minigènes codant pour des peptides, et leurs procédés d'utilisation
EP3292152A1 (en) 2015-05-07 2018-03-14 Agenus Inc. Anti-ox40 antibodies and methods of use thereof
WO2017062976A1 (en) * 2015-10-09 2017-04-13 Global Biopharma, Inc. Anti-cancer vaccine combination
JP7089470B2 (ja) 2015-12-02 2022-06-22 アジェナス インコーポレイテッド 抗体およびその使用方法
TWI765875B (zh) 2015-12-16 2022-06-01 美商磨石生物公司 新抗原辨識、製造及用途
PT3463436T (pt) 2016-06-02 2023-12-28 Ultimovacs As Uma vacina em combinação com um inibidor de ponto de verificação imune para utilização no tratamento do cancro
MX2019000215A (es) * 2016-07-05 2019-11-12 Advaxis Inc Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
EP3538152A4 (en) 2016-11-09 2020-09-30 Agenus Inc. ANTI-OX40 ANTIBODIES, ANTI-GITR ANTIBODIES AND METHOD OF USING THEREOF
KR20190082850A (ko) 2016-11-30 2019-07-10 어드박시스, 인크. 반복되는 암 돌연변이를 표적화하는 면역원 조성물 및 그것의 사용 방법
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3645039A4 (en) * 2017-06-27 2021-05-05 Neuracle Science Co., Ltd USE OF ANTI-FAM19A5 ANTIBODIES TO TREAT FIBROSIS
NZ762881A (en) 2017-09-19 2024-03-22 Advaxis Inc Compositions and methods for lyophilization of bacteria or listeria strains
EP3694532A4 (en) 2017-10-10 2021-07-14 Gritstone Oncology, Inc. IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
EP3707152A4 (en) * 2017-11-08 2021-12-01 Advaxis, Inc. IMMUNOGENIC HETEROCLITIC PEPTIDES FROM CANCER ASSOCIATED PROTEIN AND METHOD FOR THEREFORE
JP2021503897A (ja) 2017-11-22 2021-02-15 グリットストーン オンコロジー インコーポレイテッド 新生抗原のためのジャンクションエピトープ提示の低減
EP3730153A1 (en) 2019-04-26 2020-10-28 Medizinische Hochschule Hannover Personalized immunotherapy for treatment of cancer
EP3922255A1 (en) * 2020-06-10 2021-12-15 Prokarium Limited Cancer therapy
WO2023108073A2 (en) * 2021-12-10 2023-06-15 Georgiamune Llc Polypeptide modulators

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120121643A1 (en) * 2006-03-01 2012-05-17 Dubensky Jr Thomas W Engineered listeria and methods of use thereof
US9017660B2 (en) * 2009-11-11 2015-04-28 Advaxis, Inc. Compositions and methods for prevention of escape mutation in the treatment of Her2/neu over-expressing tumors

Also Published As

Publication number Publication date
CA2955432A1 (en) 2016-01-21
SG11201700090RA (en) 2017-02-27
EP3169355A4 (en) 2018-07-25
KR20170063505A (ko) 2017-06-08
JP2017522322A (ja) 2017-08-10
US20180064765A1 (en) 2018-03-08
AU2015289449A1 (en) 2017-02-09
CN106794235A (zh) 2017-05-31
IL249671A0 (en) 2017-02-28
MA40061A (fr) 2016-01-21
WO2016011362A1 (en) 2016-01-21
EP3169355A1 (en) 2017-05-24

Similar Documents

Publication Publication Date Title
MX2017000836A (es) Composiciones inmunogenicas basadas en listeria para inducir respuestas antitumorales.
MX2017008187A (es) Combinacion de vacuna basada en listeria con anticuerpos anti-ox40 o anti-gitr.
MX2016011537A (es) Metodos y composiciones para aumentar una relacion de celulas t efectoras con respecto a las celulas t reguladoras.
MA40228A (fr) Souche de listeria recombinée exprimant des protéines de fusion à antigène hétérologues et procédés pour les utiliser
MA39849A (fr) Souches de listeria utilisées comme vaccin recombinant et procédé de production
CY1122035T1 (el) Αντισωματα μονης περιοχης που κατευθυνονται εναντι ενδοκυτταρικων αντιγονων
MX2017004897A (es) Cepas vacunales recombinantes de listeria y metodos para usar las mismas en la inmunoterapia contra el cancer.
AR104635A1 (es) COMPOSICIONES A BASE DE LISTERIA INMUNOGÉNICA QUE COMPRENDEN FUSIONES DE ANTÍGENO Y ActA TRUNCADA Y MÉTODOS DE USO DE ESTAS
MX2018004598A (es) Cepas vacunales recombinantes de listeria y métodos para usar las mismas en la inmunoterapia contra el cáncer.
MX2021006017A (es) Polipeptidos de folistatina y sus usos.
EA201691631A1 (ru) Иммунотерапия рака с применением комбинации местной и системной иммунной стимуляции
MX2019000215A (es) Composiciones inmunogenicas a base de listeria que comprenden antigenos de proteinas del tumor de wilms y metodos para su uso.
MX2017011246A (es) Composiciones a base de listeria que comprenden un sistema de expresion de minigen peptidico y metodos de uso de estas.
ZA202206809B (en) Hiv vaccines comprising one or more population episensus antigens
BR112018073221A2 (pt) métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina
WO2019006401A3 (en) LISTERIA-BASED IMMUNOGENIC COMPOSITIONS COMPRISING HETERICCLIENT WILMS TUMOR PROTEIN ANTIGENS AND METHODS OF USE THEREOF
MX2019003970A (es) Péptidos de arginasa inmunogénicos.
ZA202204223B (en) Vaccination with mica/b alpha 3 domain for the treatment of cancer
WO2016011432A3 (en) Identification of immunogenic mhc class ii peptides for immune-based therapy
MX2017016438A (es) Polipeptido quimerico, vacuna contra la babesiosis, metodos de inmunizacion, metodos de deteccion y kit.
BR112017002193A2 (pt) peptídeo derivado de urlc10 e vacina contendo o mesmo
MX2016003470A (es) Identificacion de proteinas inmunogenicas para el control de ectoparasitos.
AR104231A1 (es) Proteínas de fusión inmunogénicas para el tratamiento del cáncer
MX2021001641A (es) Identificacion de proteinas inmunogenicas para el control de ectoparasitos.
IL244857B (en) A fusion protein of acetylcholinesterase and the fc region